Why the study?
Does spironolactone affect the renal clearance and plasma levels of digoxin in digitalized patients with congestive heart disease?
Does spironolactone affect the renal clearance and plasma levels of digoxin in digitalized patients with congestive heart disease?
Spironolactone inhibits the active renal tubular secretion of digoxin, leading to elevated plasma digoxin levels and highlighting a clinically significant drug-drug interaction.
Answers are grounded in this paper and cite their sources.
May warrant digoxin monitoring with spironolactone co-use in HF; leaves open magnitude of interaction and need for modern validation.
To study the mechanism of the renal handling of digoxin, simultaneous measurements of digoxin and inulin clearances were performed in 13 digitalized patients with congestive heart disease. The renal digoxin clearances exceeded inulin clearances, indicating an active tubular secretion of digoxin. No evidence of tubular backward diffusion was disclosed. Treatment with spironolactone (Aldactone) decreased the digoxin clearances, suggesting an inhibition of the tubular secretion of digoxin in the distal segment of the renal tubulus. After blocking the tubular secretion, the calculated renal clearances of nonproteinbound digoxin in plasma were similar to that of inulin, suggesting a glomerular filtration of free plasma digoxin. Plasma digoxin level rose during treatment with spironolactone.
No takes yet. Share an insight, caveat, or question.
Eva Steiness (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: